K Hisamatsu

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer

Takayuki Ueno, Norikazu Masuda, Takeharu Yamanaka et al. · International Journal of Clinical Oncology · 2013 · 64 citations

Breast Oncology, Neoadjuvant Exemestane, Medicine +10

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Shinji Ohno, Louis W.C. Chow, Nobuaki Sato et al. · Breast Cancer Research and Treatment · 2013 · 55 citations · Full text

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

Katsumasa Kuroi, Kojiro Shimozuma, Yasuo Ohashi et al. · Supportive Care in Cancer · 2008 · 52 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition

Masakazu Toi, Shigehira Saji, Norikazu Masuda et al. · Cancer Science · 2011 · 50 citations · Full text

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

Tomohiko Aihara, Yuichi Takatsuka, Shozo Ohsumi et al. · Breast Cancer Research and Treatment · 2010 · 49 citations

Breast Oncology, Versus Sequential Tamoxifen, Medicine +12